基于改进剩余收益法的医药企业价值研究  

Research on the Value of Pharmaceutical Enterprises Based on Improved Residual Income Method

作　　者：吴世玉 管仕平[1] WU Shiyu;GUAN Shiping(Guangxi University of Science and Technology,Liuzhou 545000,China)

机构地区：[1]广西科技大学,广西柳州545000

出　　处：《商业观察》2023年第35期108-112,共5页BUSINESS OBSERVATION

摘　　要：基于生物医药企业进入壁垒高、研发成本大和相关领域的不断变化和更新的行业特征,生物医药企业的价值评估不能采用传统的企业价值评估方法,文章通过引入杜邦分析法、市净率及相关权重计算方法来改进剩余收益模型以解决生物医药行业的企业价值评估问题,并通过相关案例来验证改进后的模型在生物医药企业价值评估应用中的适用性和准确性。Based on the characteristics of bio-pharmaceutical enterprises such as high barriers to entry,high R&D costs and the constantly changing and updated industries in related fields,traditional enterprise value evaluation methods cannot be used for the value evaluation of bio-pharmaceutical enterprises.In this paper,DuPont analysis,P/B ratio and related weight calculation methods are introduced to improve the residual income model to solve the problem of enterprise value evaluation in the bio-pharmaceutical industry.The paper verifies the applicability and accuracy of the improved model in the value evaluation application of bio-pharmaceutical enterprises through relevant cases.

关 键 词：剩余收益模型 实物期权 生物医药企业 企业价值研究 

分 类 号：F275[经济管理—企业管理]